glp-1 obesity drug news today september 15 2025 The first of three of our Appetite for Answers series! Understanding GLP-1s Beyond the Headlines medications are currently a major topic of discussion, and unfortunately, misinformation is spreading—not only among the New Guidelines on GLP-1 Drugs

162,163 Retatrutide (LY-3437943), a novel triple agonist developed by Eli Lilly that targets GLP-1R, GIPR and GCGR, has shown potential in preliminary clinical data for providing excellent blood sugar control and significant weight reduction

L-Carnitines Role : Ensures your body is efficiently using its existing fat stores for fuel

Diagnosis and treatment of vitamin B 12 deficiency-an update

How is AOD-9604 different from CJC-1295/Ipamorelin

its essential for anyone pursuing metabolic health and longevity

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo